Leptomeningeal infiltration is a rare complication of multiple myeloma (MM) that portends an extremely poor prognosis. The true incidence is unknown with few literature reports. We report a case of leptomeningeal relapse of MM post allogeneic stem cell transplant (alloSCT), which was successfully treated with a single dose of intrathecal methotrexate and total craniospinal irradiation (CSI) supported by second allogeneic donor stem cell infusion (SCI). To our knowledge, this is the first report of a second allogeneic SCI for this condition. We postulate that a graft-versus-myeloma (GVM) effect may be playing an important role in sustaining the response and conclude that CSI followed by a second allogeneic SCI is an appropriate treatment option in patients with leptomeningeal myelomatosis in the setting of prior alloSCT. The donor SCI may serve to enhance haematopoiesis recovery as well as inducing a GVM effect.
This man was 42 years old when diagnosed with stage III myeloma, presenting as kappa light chain Bence Jones Protein (BJP) and diffuse skeletal disease. He achieved a partial response (PR) following local radiotherapy (RT) and 8 months of intermittent melphalan and prednisolone, then proceeded to a matched-sibling alloSCT with busulphan and cyclophosphamide conditioning. Subsequent graft-versus-host disease (GVHD), manifested by deranged liver function, oral ulcers and diarrhoea, required 3 years of low-dose immunosuppression that was successfully discontinued. After a 4-year disease-free interval, he developed diffuse lytic bone disease, BJP of 0.17 g/l and a 4 cm extramedullary gastrocnemius plasmacytoma. Bone marrow demonstrated 25% plasmacytosis. Following treatment for 8 weeks on an escalating dose of thalidomide to 800 mg on a phase II clinical trial, 1 the plasmacytoma reduced to o2 cm and marrow infiltration to 5%. After 11 months of stable disease on Thalidomide and Interferon, multiple relapses occurred with proteinuria, bony disease and soft tissue scalp plasmacytomas, which were stabilized at different times with local RT, VAD chemotherapy, and weekly cyclophosphamide (500 mg) with daily prednisolone over the following 2.5 years. He then presented with 4 weeks of bilateral leg weakness that progressed to an inability to weight bear, associated with worsening diplopia on upward and right sided gaze. Marked bilateral proximal leg weakness with normal knee and ankle reflexes were also evident.
Laboratory investigations demonstrated a serum IgG kappa paraprotein of 1 g/l, and urinary protein of 0.14 g/l with 70% free kappa light chains. Bone marrow demonstrated o5% malignant plasma cells with cytogenetics showing all metaphases bearing a 100% female karyotype. Calcium and beta 2 microglobulin were normal; lactate dehydrogenase (LDH) was twice the upper limit of normal range. Haemaglobin (Hb) 147 g/l; total white cell count (WCC) 10.2 Â 10 9 /l; absolute neutrophil count (ANC) 8.9 Â 10 9 /l; platelets 156 Â 10 9 /l. Magnetic resonance imaging demonstrated abnormal meningeal enhancement along the lower spinal cord from T12 down to the conus. Intradural extramedullary deposits at L1/L2 were seen in association with nerve root involvement. No intracranial lesions were found, and no abnormality along the course of the third cranial nerve to explain the partial left third nerve palsy. Cerebrospinal fluid examination (with co-administration of 12 mg intrathecal methotrexate) revealed malignant plasma cells with an elevated total protein. Leptomeningeal dissemination of MM was diagnosed.
The patient immediately commenced oral dexamethasone and 30 Gy CSI, consisting of 20 fractions over 4 weeks. A rapid response was observed with resolution of diplopia after 1 week of treatment. Within 10 days of commencing radiotherapy, pancytopenia developed. Platelet support was required during RT to maintain platelets above 10 Â 10 9 /l. His sister (original donor) underwent G-CSF stem cell mobilization. The patient was infused with 4.37 Â 10 6 CD34 þ cells per kilogram recipient body weight (day 0). GCSF was commenced on day 1. No GVHD prophylaxis administered. On day 13 the ANC exceeded 1.0 Â 10 9 /l and on day 16 the platelets exceeded 20 Â 10 9 /l, independent of transfusions.
During the first 100 days, grade II GVHD of mouth, liver and gut developed, which responded to intermittent steroids. Now, 9 months post commencement of RT, the patient remains transfusion independent with normal Hb, WCC and platelets of 102 Â 10 9 /l, on prednisolone 50 mg alternate days. The diplopia and ptosis have fully resolved and he is able to walk independently.
Leptomeningeal involvement is extremely rare in MM. The small number of cases reported generally occurred in the setting of pre-existing stage III MM 2-4 associated with an elevated LDH level, 5, 6 unfavourable cytogenetic abnormalities 6 and plasma cell leukemia. 4, 6 Not surprisingly, the prognosis is extremely poor. Based on previously reported cases and accepting the bias for reporting only responding patients, Peterson et al 7 estimated the median overall survival to be only 1.5 months from the time of diagnosis of meningeal involvement.
Reported treatments are heterogenous, but generally include various combinations of intrathecal methotrexate, hydrocortisone, thiotepa, cytarabine and CSI. [2] [3] [4] [5] [6] [7] [8] Often, transient neurological improvement is seen, but progression and death inevitably follow shortly after.
In line with the reported literature, our patient developed leptomeningeal disease in the setting of recurrent relapses, 8 years after alloSCT. Sustained neurological improvement was seen after treatment with a single dose of intrathecal methrotrexate, and CSI followed by a second allogeneic stem cell infusion (SCI). He continues to improve 9 months post the commencement of radiotherapy.
Given the inherent radiotherapy sensitivity of myeloma and the poor prognosis of chemotherapy in leptomeningeal disease, we felt that CSI would offer this patient the best chance of durable remission. However, we anticipated that the CSI would render him severely pancytopenic. Considering the limited GVHD he had suffered from his prior alloSCT, we elected to infuse his sister's cells without GVHD prophylaxis in the hope of enhancing hematopoietic recovery and inducing a moderate GVM effect without substantial GVHD. 9 Given the generally poor outcome previously demonstrated with CSI alone, we postulate that a GVM effect may have played an important part in his sustained response.
We conclude that CSI followed by donor SCI in the setting of subsequent myelosuppression is an appropriate treatment option in patients with leptomeningeal relapse post alloSCT. Donor SCI serves not only to enhance haematopoietic recovery, but to also induce a GVM effect. 
